L-selenomethionine reduces platinum(IV) anticancer model compounds at strikingly faster rates than L-methionine

L-Selenomethionine (SeMet), the predominant form of selenium acquired from the diet by humans, has been used as a supplement, and exhibit some important functions like cancer prevention and antioxidative defense. Its interactions with Pt(II) anticancer drugs have been characterized, but its redox re...

Full description

Saved in:
Bibliographic Details
Published in:Dalton transactions : an international journal of inorganic chemistry Vol. 43; no. 41; p. 15328
Main Authors: Huo, Shuying, Dong, Jingran, Shen, Shigang, Ren, Yanli, Song, Changying, Xu, Jianzhong, Shi, Tiesheng
Format: Journal Article
Language:English
Published: England 07-11-2014
Subjects:
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract L-Selenomethionine (SeMet), the predominant form of selenium acquired from the diet by humans, has been used as a supplement, and exhibit some important functions like cancer prevention and antioxidative defense. Its interactions with Pt(II) anticancer drugs have been characterized, but its redox reactions with platinum(IV) anticancer prodrugs have not been exploited. In this work, the oxidation of SeMet by Pt(IV) anticancer model compounds trans-[PtX2(CN)4](2-) (X = Cl, Br) was characterized. A stopped-flow spectrometer was used to record the rapid scan spectra and to follow the reaction kinetics over a wide pH range. An overall second-order rate law was derived: -d[Pt(IV)]/dt = k'[Pt(IV)][SeMet], where k' pertains to the observed second-order rate constants. The k'-pH profiles showed that k' increased only about 6 times even though the solution pH was varied from 0.25 to 10.5. The redox stoichiometry was determined as Δ[Pt(IV)]/Δ[SeMet] = 1 : (1.07 ± 0.07), suggesting that SeMet was oxidized to selenomethionine selenoxide. The selenoxide together with its hydrated form was identified explicitly by high resolution mass spectral analysis. A reaction mechanism was proposed which encompassed three parallel rate-determining steps relying on the protolytic species of SeMet. Rate constants of the rate-determining steps were obtained from the simulations of the k'-pH profiles. Activation parameters were determined for the reactions of the zwitterionic form of SeMet with the Pt(IV) complexes. A bridged electron transfer process is delineated in the rate-determining steps and several lines of evidence support the bridged electron transfer mode. Strikingly, reduction of [PtX2(CN)4](2-) by SeMet is 3.7 × 10(3)-5.7 × 10(4) times faster than that by L-methionine. Some potential biological consequences resulting from the strikingly fast reduction are discussed.
AbstractList L-Selenomethionine (SeMet), the predominant form of selenium acquired from the diet by humans, has been used as a supplement, and exhibit some important functions like cancer prevention and antioxidative defense. Its interactions with Pt(II) anticancer drugs have been characterized, but its redox reactions with platinum(IV) anticancer prodrugs have not been exploited. In this work, the oxidation of SeMet by Pt(IV) anticancer model compounds trans-[PtX2(CN)4](2-) (X = Cl, Br) was characterized. A stopped-flow spectrometer was used to record the rapid scan spectra and to follow the reaction kinetics over a wide pH range. An overall second-order rate law was derived: -d[Pt(IV)]/dt = k'[Pt(IV)][SeMet], where k' pertains to the observed second-order rate constants. The k'-pH profiles showed that k' increased only about 6 times even though the solution pH was varied from 0.25 to 10.5. The redox stoichiometry was determined as Δ[Pt(IV)]/Δ[SeMet] = 1 : (1.07 ± 0.07), suggesting that SeMet was oxidized to selenomethionine selenoxide. The selenoxide together with its hydrated form was identified explicitly by high resolution mass spectral analysis. A reaction mechanism was proposed which encompassed three parallel rate-determining steps relying on the protolytic species of SeMet. Rate constants of the rate-determining steps were obtained from the simulations of the k'-pH profiles. Activation parameters were determined for the reactions of the zwitterionic form of SeMet with the Pt(IV) complexes. A bridged electron transfer process is delineated in the rate-determining steps and several lines of evidence support the bridged electron transfer mode. Strikingly, reduction of [PtX2(CN)4](2-) by SeMet is 3.7 × 10(3)-5.7 × 10(4) times faster than that by L-methionine. Some potential biological consequences resulting from the strikingly fast reduction are discussed.
Author Huo, Shuying
Shi, Tiesheng
Dong, Jingran
Shen, Shigang
Xu, Jianzhong
Ren, Yanli
Song, Changying
Author_xml – sequence: 1
  givenname: Shuying
  surname: Huo
  fullname: Huo, Shuying
  email: shensg@hbu.edu.cn, rock@hbu.edu.cn
  organization: College of Chemistry and Environmental Science, and the MOE Key Laboratory of Medicinal Chemistry and Molecular Diagnostics, Hebei University, Baoding 071002, Hebei Province, P. R. China. shensg@hbu.edu.cn rock@hbu.edu.cn
– sequence: 2
  givenname: Jingran
  surname: Dong
  fullname: Dong, Jingran
– sequence: 3
  givenname: Shigang
  surname: Shen
  fullname: Shen, Shigang
– sequence: 4
  givenname: Yanli
  surname: Ren
  fullname: Ren, Yanli
– sequence: 5
  givenname: Changying
  surname: Song
  fullname: Song, Changying
– sequence: 6
  givenname: Jianzhong
  surname: Xu
  fullname: Xu, Jianzhong
– sequence: 7
  givenname: Tiesheng
  surname: Shi
  fullname: Shi, Tiesheng
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25075569$$D View this record in MEDLINE/PubMed
BookMark eNpFj81KxDAYRYMozji68QEkS11Uk_QnyVIGfwYKbtTt8CX5xom2SWnSxby9BRVXFw6XA-eMHIcYkJBLzm45K_WdrVxmvBbKHJElr6QstCirBTlL6ZMxIVgtTslC1EzWdaOXJLZFwg5D7DHvfQw-IB3RTRYTHTrIPkz99eb9hkLI3kKwONI-Ouyojf0Qp-AShUxTHv2XDx_dge4g5fk0Qp4VeQ-BtsW__Jyc7KBLePG7K_L2-PC6fi7al6fN-r4trFAyF2BcqXSllZJ10wjFDQdV6bJRIJ0wHI3kUM7QqEbqHZi5R0ElmJIatZViRa5-vMNkenTbYfQ9jIftX7n4BpGEW88
CitedBy_id crossref_primary_10_1039_C5NJ01103E
crossref_primary_10_1016_j_bmcl_2016_07_046
crossref_primary_10_1007_s11243_019_00347_x
crossref_primary_10_1039_C8CC05682J
crossref_primary_10_1007_s11243_015_9923_4
crossref_primary_10_1007_s11243_017_0125_0
crossref_primary_10_1016_j_molliq_2020_115195
crossref_primary_10_1007_s11243_016_0021_z
crossref_primary_10_1039_c5mt00116a
crossref_primary_10_1007_s11243_019_00311_9
crossref_primary_10_1039_C7DT00885F
crossref_primary_10_2174_2212796816666220422134828
crossref_primary_10_1007_s11243_015_9995_1
crossref_primary_10_1021_acs_joc_3c00104
crossref_primary_10_1039_C6DT01804A
crossref_primary_10_1016_j_molliq_2018_09_056
crossref_primary_10_1002_kin_21107
crossref_primary_10_1021_acs_joc_1c02793
crossref_primary_10_1016_j_saa_2019_117328
crossref_primary_10_1093_mtomcs_mfad020
crossref_primary_10_1007_s11243_015_9983_5
crossref_primary_10_1016_j_molliq_2019_112105
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1039/c4dt01528b
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Chemistry
EISSN 1477-9234
ExternalDocumentID 25075569
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-DZ
-JG
-~X
0-7
0R~
29F
2WC
4.4
53G
5GY
70~
7~J
AAEMU
AAIWI
AAJAE
AAMEH
AANOJ
AAWGC
AAXHV
AAXPP
ABASK
ABDVN
ABEMK
ABJNI
ABPDG
ABRYZ
ABXOH
ACGFS
ACIWK
ACLDK
ACNCT
ADMRA
ADSRN
AEFDR
AENEX
AENGV
AESAV
AETIL
AFLYV
AFOGI
AFRDS
AFVBQ
AGEGJ
AGKEF
AGRSR
AHGCF
ALMA_UNASSIGNED_HOLDINGS
ANBJS
ANUXI
APEMP
ASKNT
AUDPV
AZFZN
BLAPV
BSQNT
C6K
CGR
CS3
CUY
CVF
D0L
DU5
EBS
ECGLT
ECM
EE0
EF-
EIF
EJD
F5P
GGIMP
GNO
H13
HZ~
H~N
IDZ
J3G
J3H
J3I
M4U
NPM
O9-
R7B
R7C
RAOCF
RCNCU
RNS
ROL
RPMJG
RRA
RRC
RSCEA
SKA
SKF
SLH
TN5
TWZ
UCJ
UPT
VH6
VQA
WH7
XOL
ID FETCH-LOGICAL-c287t-abd38949887566281b1a849368a7d2b1eb71a3b1ab8679fab0758a420879e9c72
IngestDate Sat Sep 28 08:04:48 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 41
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c287t-abd38949887566281b1a849368a7d2b1eb71a3b1ab8679fab0758a420879e9c72
PMID 25075569
ParticipantIDs pubmed_primary_25075569
PublicationCentury 2000
PublicationDate 2014-11-07
PublicationDateYYYYMMDD 2014-11-07
PublicationDate_xml – month: 11
  year: 2014
  text: 2014-11-07
  day: 07
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Dalton transactions : an international journal of inorganic chemistry
PublicationTitleAlternate Dalton Trans
PublicationYear 2014
SSID ssj0022052
Score 2.2907429
Snippet L-Selenomethionine (SeMet), the predominant form of selenium acquired from the diet by humans, has been used as a supplement, and exhibit some important...
SourceID pubmed
SourceType Index Database
StartPage 15328
SubjectTerms Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Drug Interactions
Methionine - chemistry
Methionine - pharmacology
Models, Molecular
Organoplatinum Compounds - chemistry
Organoplatinum Compounds - pharmacology
Oxidation-Reduction
Selenomethionine - chemistry
Selenomethionine - pharmacology
Spectrophotometry
Title L-selenomethionine reduces platinum(IV) anticancer model compounds at strikingly faster rates than L-methionine
URI https://www.ncbi.nlm.nih.gov/pubmed/25075569
Volume 43
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LTxsxELaScmgvqKUvKFQ-9FC0sprd9eLdYxVSgQQcGkDtCfm1AoluIpIc-PfM-BEHUKty4LKKxs5u4vlijyee7yPki8htK0VVsVaUmvG2HDDFK8GM2LNWV0Zppw14MBYnv-r9ER_1erH-Ptme1dNgA19j5ewTvL28KRjgNfgcruB1uP6X348Y6id1E5SGdrlW1EUxCzx4NcVzbx0KG9eH55gOgFHFWVDbG6-I4w6Yo87SDGscUdEDE-nXt1krkU8hQ1qJWYbJ9uyIpQesBrj7EmWqUXkiypDPXNZBdo6ZIiUf71FWeG0pnekoP5fQ5lK548vFbVxjMeqO54jBdpPgPQ6VJuPLK7jdsvdPb_0tu-ur1SRHzl21n1-IrZ-YOf7VXITEZ5i5PcFTQKjnzwrzMMzjvub80QoxKJFgVXMzh0CoqO8tIzAc0z8OFxAYAoC9iMy_Wx-wdcemPulD7IXh-fB4mQAoBlURKXLL5lv6EEhJHd74YHvjwpzT12Q97E_odw-sN6Rnuw3ychj98pZMHgOMBoDRCLCvh-e7NIGLOnDRJbionNMELurBRR24KIKLroLrHTn7MTodHrCg2sE07L7nTCoDQTBvYPWCrUIB26Jc1rwp92opTKFyq0QuSzAq5HpspYLvXUs85SEa22hRvCcvuklnPxKqStUaWZpK25Zb6Au9C5FXtpLQUzeb5IMfq4upp2a5iKO49deWT-RVAtg2WWvhd293SH9mFp-dt-4AVOaBgg
link.rule.ids 782
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=L-selenomethionine+reduces+platinum%28IV%29+anticancer+model+compounds+at+strikingly+faster+rates+than+L-methionine&rft.jtitle=Dalton+transactions+%3A+an+international+journal+of+inorganic+chemistry&rft.au=Huo%2C+Shuying&rft.au=Dong%2C+Jingran&rft.au=Shen%2C+Shigang&rft.au=Ren%2C+Yanli&rft.date=2014-11-07&rft.eissn=1477-9234&rft.volume=43&rft.issue=41&rft.spage=15328&rft_id=info:doi/10.1039%2Fc4dt01528b&rft_id=info%3Apmid%2F25075569&rft_id=info%3Apmid%2F25075569&rft.externalDocID=25075569